Neurostimulation devices have moved from a niche corner of medical technology into one of the more closely watched segments in healthcare. The global neurostimulation devices market is estimated to grow from US$6.7 billion in 2024 to US$14.6 billion by 2031, expanding at a CAGR of 11.7% in the forecast period, according to Persistence Market Research. Behind this astonishing growth is a wave of new approvals, intense competition, and a genuine shift in how these devices are designed and delivered.
Adaptive Neurostimulation is Setting a New Standard
For years, progress in the global market meant shrinking hardware and stretching battery life. This is still happening, but the key concept now is intelligence. In February 2025, Medtronic received the U.S. Food and Drug Administration (FDA) approval for BrainSense Adaptive deep brain stimulation. It is a system that senses a patient's brain activity in real time and adjusts stimulation automatically, rather than delivering a fixed, constant signal. It is the medical device equivalent of moving from a manual gearbox to an automatic one, and it took Medtronic more than a decade of research to get there.
Spinal cord stimulation has followed a similar path. Closed-loop systems that respond to a patient's own signals are replacing aging devices that stimulate at a fixed rate regardless of how the patient's body is actually responding. Twelve-month data released on Medtronic's Inceptiv system showed the large majority of patients experienced less overstimulation and meaningful reductions in low-back pain, numbers that matter a great deal to physicians deciding which system to recommend.
Neurostimulation is Finding Its Way into Patients' Homes
Perhaps the most striking shift in recent years has nothing to do with implants at all. In December 2025, the FDA cleared Flow Neuroscience's FL-100 headset, the first at-home brain stimulation device approved for depression. Patients use it under a clinician's remote supervision instead of visiting an office multiple times a week, which has historically been one of the prominent barriers to treatments such as transcranial magnetic stimulation. Flow's leadership has been direct about the goal. It aims to make a therapy that once required weeks of clinic visits accessible to people who simply cannot get there.
This home-use trend is not limited to depression. Wearable, drug-free devices such as Quell and CEFALY were already giving patients a way to manage chronic pain and migraines without a prescription pad, and their growing popularity signals where demand is heading. As more of these devices earn regulatory clearance, neurostimulation is starting to look less like a hospital procedure and more like a category of consumer health technology.
Big Players Are Expanding Through Strategic Deals
Behind the clinical headlines, the business side of the global market has been just as active. In February 2025, Globus Medical agreed to acquire Nevro, a long-time spinal cord stimulation specialist, in a US$250 million deal. Nevro had spent months exploring a sale after tougher competition from Medtronic and Boston Scientific squeezed its market share and compelled it to cut its own revenue guidance. For Globus, a company built around spine surgery hardware, the deal was a way to move into neuromodulation without building that expertise from scratch.
Boston Scientific has taken a similar approach, expanding beyond its core neurostimulation business by acquiring Axonics to strengthen its position in sacral neuromodulation and bowel and bladder therapies. These deals point to a broad pattern. Rather than compete purely on incremental device improvements, renowned players are buying their way into adjacent therapy areas, betting that patients and hospitals now prefer one vendor who can address multiple conditions.
Insurance Coverage Continues to Influence Patient Adoption
None of the innovation matters much if patients cannot afford it. Favorable coverage from Medicare for spinal cord stimulation and dorsal root ganglion therapy has been central to the market's growth in the U.S., and private insurers have gradually followed suit. Even so, the cost of implantable systems, the specialized training clinicians need, and the ongoing monitoring these devices require keep them out of reach for many patients, mainly outside North America and Europe.
This gap is part of why home-use and wearable devices matter beyond convenience. A device a patient can use without surgery, hospital admission, or repeated clinic visits sidesteps several of the cost barriers that have limited access for years. It is a slow, less dramatic kind of progress than a new implant, but it may end up reaching far more people.
The Future of Neurostimulation is More Adaptive
Neurostimulation is no longer just about implanting a device and hoping it helps. It is about devices that sense, adapt, and constantly work from a patient's own home, backed by companies that are actively transforming their portfolios through acquisitions rather than organic growth alone. Chronic pain, Parkinson's disease, depression, and epilepsy remain the conditions propelling demand, but the way these therapies reach patients is changing faster than the underlying technology itself. For a market built on rewiring how the nervous system responds to disease, this shift feels fitting.
